Glaukos Corp. (NYSE:GKOS) CEO Thomas William Burns sold 200,120 shares of the stock in a transaction on Tuesday, November 15th. The stock was sold at an average price of $33.68, for a total value of $6,740,041.60. Following the completion of the sale, the chief executive officer now directly owns 1,388 shares in the company, valued at $46,747.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Glaukos Corp. (NYSE:GKOS) opened at 33.24 on Thursday. The firm has a 50-day moving average price of $35.31 and a 200 day moving average price of $31.28. The stock’s market capitalization is $1.10 billion. Glaukos Corp. has a 12 month low of $14.25 and a 12 month high of $39.82.

Glaukos Corp. (NYSE:GKOS) last released its quarterly earnings results on Thursday, November 10th. The company reported $0.03 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.00 by $0.03. The firm earned $29.60 million during the quarter, compared to analyst estimates of $27.21 million. Glaukos Corp. had a return on equity of 2.11% and a net margin of 2.07%. The business’s revenue for the quarter was up 55.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.07) EPS. Equities analysts anticipate that Glaukos Corp. will post $0.12 earnings per share for the current year.

Insider Buying and Selling by Quarter for Glaukos Corp. (NYSE:GKOS)

Several equities research analysts recently commented on GKOS shares. Cantor Fitzgerald increased their price objective on Glaukos Corp. to $45.00 in a research report on Friday, November 11th. Piper Jaffray Cos. increased their price objective on Glaukos Corp. to $42.00 in a research report on Tuesday, August 2nd. Zacks Investment Research raised Glaukos Corp. from a “hold” rating to a “buy” rating and set a $37.00 price objective on the stock in a research report on Thursday, August 4th. Roth Capital increased their price objective on Glaukos Corp. from $36.50 to $41.00 and gave the company a “buy” rating in a research report on Tuesday, August 2nd. Finally, Stifel Nicolaus reaffirmed a “hold” rating on shares of Glaukos Corp. in a research report on Tuesday, September 27th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $38.80.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Credit Suisse AG raised its position in Glaukos Corp. by 496.9% in the third quarter. Credit Suisse AG now owns 74,648 shares of the company’s stock valued at $2,817,000 after buying an additional 62,143 shares during the last quarter. Bamco Inc. NY raised its position in Glaukos Corp. by 381.8% in the third quarter. Bamco Inc. NY now owns 115,261 shares of the company’s stock valued at $4,350,000 after buying an additional 91,336 shares during the last quarter. Picton Mahoney Asset Management raised its position in Glaukos Corp. by 474.6% in the third quarter. Picton Mahoney Asset Management now owns 40,800 shares of the company’s stock valued at $1,540,000 after buying an additional 33,700 shares during the last quarter. Jane Street Group LLC bought a new position in Glaukos Corp. during the third quarter valued at approximately $263,000. Finally, D. E. Shaw & Co. Inc. raised its position in Glaukos Corp. by 19.6% in the third quarter. D. E. Shaw & Co. Inc. now owns 20,486 shares of the company’s stock valued at $773,000 after buying an additional 3,361 shares during the last quarter. 70.72% of the stock is owned by hedge funds and other institutional investors.

Glaukos Corp. Company Profile

Glaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent, an MIGS device measuring approximately one millimeter long and approximately 0.33 millimeter wide.

5 Day Chart for NYSE:GKOS

Receive News & Stock Ratings for Glaukos Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corp. and related stocks with our FREE daily email newsletter.